Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regulus Therapeutics (RGLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,078
  • Shares Outstanding, K 104,800
  • Annual Sales, $ 70 K
  • Annual Income, $ -71,910 K
  • 36-Month Beta 1.44
  • Price/Sales 359.52
  • Price/Cash Flow N/A
  • Price/Book 2.47
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.60
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/07/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.11
  • Number of Estimates 3
  • High Estimate -0.06
  • Low Estimate -0.17
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +38.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.17 +58.82%
on 08/14/18
0.31 -14.29%
on 08/17/18
-0.01 (-3.57%)
since 07/20/18
3-Month
0.17 +58.82%
on 08/14/18
0.79 -65.82%
on 06/06/18
-0.45 (-62.29%)
since 05/18/18
52-Week
0.17 +58.82%
on 08/14/18
1.52 -82.24%
on 10/02/17
-0.56 (-67.47%)
since 08/18/17

Most Recent Stories

More News
Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates

Regulus (RGLS) delivered earnings and revenue surprises of 18.75% and -10.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

RGLS : 0.27 (-5.92%)
Regulus Reports Second Quarter 2018 Financial Results and Recent Updates

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the second...

RGLS : 0.27 (-5.92%)
What's in the Cards for Merck KGaA (MKGAF) in Q2 Earnings?

Merck's (MKGAF) Healthcare and Life Science segments are expected to drive sales in Q2. However, higher operating expense to support Bavencio and Mavenclad launch is expected to weigh on performance.

PG : 83.64 (-0.06%)
MDGL : 234.20 (-1.52%)
RGLS : 0.27 (-5.92%)
MKGAF : 103.1500 (+1.28%)
Free Technical Reports on 22nd Century Group and Three Additional Biotech Equities

Stock Research Monitor: RGNX, RGLS, and ABEO

XXII : 2.28 (-2.15%)
RGNX : 65.95 (unch)
RGLS : 0.27 (-5.92%)
Regulus Stock Plunges on Cash Concerns Despite Restructuring

Regulus Therapeutics (RGLS) announces strategic and restructuring plans to extend cash runway. However, investors remain skeptical.

ALNY : 96.37 (+1.89%)
IONS : 51.67 (+1.63%)
RGLS : 0.27 (-5.92%)
SNY : 42.22 (+0.43%)
Investors look to Lighten Up on Shares of Regulus Therapeu, Shares Down 42.7% (RGLS)

Regulus Therapeu (NASDAQ:RGLS) is one of today's worst performing penny stocks, down 42.7% to $0.42 on 4.0x average daily volume. Thus far today, Regulus Therapeu has traded 790,000 shares, vs. average...

RGLS : 0.27 (-5.92%)
Regulus Announces Strategic Update and Corporate Restructuring

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced a strategic update and corporate...

RGLS : 0.27 (-5.92%)
New Research: Key Drivers of Growth for CNA Financial, AutoNation, Hess, Infinity Pharmaceuticals, Regulus Therapeutics, and Weyerhaeuser -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CNA Financial Corporation (NYSE:CNA),...

WY : 35.49 (-0.45%)
CNA : 45.56 (-0.04%)
HES : 62.96 (+0.98%)
INFI : 1.93 (-3.50%)
RGLS : 0.27 (-5.92%)
AN : 46.83 (+0.97%)
Report: Developing Opportunities within Regulus Therapeutics, Airgain, Michael Kors, Heritage Insurance, CDK Global, and MedEquities Realty Trust -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Regulus Therapeutics Inc. (NASDAQ:RGLS),...

AIRG : 12.00 (+0.50%)
KORS : 74.95 (+2.70%)
RGLS : 0.27 (-5.92%)
CDK : 61.60 (-0.40%)
HRTG : 15.50 (+0.06%)
MRT : 10.42 (+0.97%)
Regulus Reports First Quarter 2018 Financial Results and Pipeline Progress

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the first quarter...

RGLS : 0.27 (-5.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade RGLS with:

Business Summary

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and...

See More

Key Turning Points

2nd Resistance Point 0.32
1st Resistance Point 0.30
Last Price 0.27
1st Support Level 0.25
2nd Support Level 0.22

See More

52-Week High 1.52
Fibonacci 61.8% 1.00
Fibonacci 50% 0.84
Fibonacci 38.2% 0.69
Last Price 0.27
52-Week Low 0.17

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar